Ikobel

Tobramycin, the active ingredient in Ikobel, is an aminoglycoside presented as an ophthalmic solution for ocular use. It treats bacterial infections of the eye such as conjunctivitis, keratitis and corneal ulcers, primarily in adult and pediatric patients where a topical antibiotic is indicated.

GNH USA supplies Ikobel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Customers benefit from reliable logistics, comprehensive documentation, and responsive technical support throughout the supply chain.

Ikobel (tobramycin) is an aminoglycoside antibiotic formulated for ophthalmic use, employed to treat a range of bacterial infections affecting the eye's surface and cornea.

- Bacterial conjunctivitis: reduces bacterial load, alleviates redness and discharge, and promotes rapid resolution of infection. - Keratitis: eradicates causative Gram‑negative organisms, limiting corneal inflammation and preventing stromal damage. - Corneal ulcer: penetrates ulcerated tissue to eliminate infection, supporting re‑epithelialisation and visual recovery. - Post‑operative ocular infection: applied prophylactically to reduce risk of bacterial colonisation after eye surgery. - Bacterial blepharitis: helps control infection of eyelid margins.

Topical tobramycin may cause ocular discomfort and, in rare cases, more severe reactions.

Common Side Effects: - Eye irritation: transient burning, stinging or itching sensation that usually resolves after continued use. - Redness: mild conjunctival hyperemia causing the eye to appear pink. - Tearing: increased lacrimation leading to watery eyes during treatment. - Blurred vision: temporary visual disturbance that clears once the drop is absorbed.

Serious or Rare Side Effects: - Allergic reaction: swelling of the eyelid, itching, rash or hives that may require immediate discontinuation and medical attention. - Corneal ulcer worsening: progression of the ulcer or development of a new ulcer despite therapy, indicating possible resistance. - Systemic toxicity: rare systemic absorption leading to nephrotoxicity or ototoxicity, especially in patients with renal impairment.

When using Ikobel, certain precautions help ensure safety and effectiveness.

- Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown excretion in milk; consider alternative therapy or monitor infant. - Renal impairment: monitor for systemic absorption and adjust therapy as needed. - Contact lens wearers: avoid wearing lenses until treatment is completed and the eye is clear. - Allergy: discontinue immediately if signs of hypersensitivity such as swelling or rash appear. - Store below 25°C: keep in original container, protect from light and moisture.

Tobramycin may interact with other medicines, affecting its safety profile.

Major Interactions (Avoid): - Nephrotoxic drugs (e.g., aminoglycosides, vancomycin): increased risk of kidney toxicity. - Loop diuretics (e.g., furosemide): heightened nephrotoxicity when combined. - Neuromuscular blocking agents: may potentiate neuromuscular blockade leading to respiratory weakness.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: can mask infection signs and reduce antibiotic efficacy. - Other ophthalmic antibiotics: potential antagonism or additive toxicity. - Systemic aminoglycosides: cumulative exposure may increase systemic toxicity. - Anticholinergic eye drops: may affect tear film and drug distribution.